Anbio Biotechnology (NNNN) Accounts Payables (2023 - 2025)

Anbio Biotechnology has reported Accounts Payables for 3 years, with the latest figure at $60350.0 in Q2 2025.

• On a quarterly basis, Accounts Payables changed N/A year-over-year to $60350.0 in Q2 2025; TTM through Jun 2025 was $60350.0, a N/A change from a year earlier, with the FY2024 full-year figure at $1.6 million, up 96.49% from the prior year.
• Accounts Payables was $60350.0 for Q2 2025 at Anbio Biotechnology, down from $1.6 million in the prior quarter.
• The five-year high for Accounts Payables was $1.6 million in Q4 2024, with the low at $60350.0 in Q2 2025.
• Average Accounts Payables over 3 years is $837585.3, with a median of $827151.0 recorded in 2023.
• The largest YoY upside for Accounts Payables was 96.49% in 2024 against a maximum downside of 96.49% in 2024.
• Over 3 years, Accounts Payables stood at $827151.0 in 2023, then jumped by 96.49% to $1.6 million in 2024, then slumped by 96.29% to $60350.0 in 2025.
• The last three Accounts Payables figures came in at $60350.0 (Q2 2025), $1.6 million (Q4 2024), and $827151.0 (Q4 2023), per Business Quant data.